Mode
Text Size
Log in / Sign up
N/A N=23 Randomized Double-blind Other

Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty

Knee Osteoarthristis

Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Neuromuscular electrical stimulation (Device)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
University of Vermont
Primary completion
Jun 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Cross-sectional Area (CSA) of Muscle Fibers
2680; 2377; 2028; 1882; 2039; 1971
PRIMARY
Intermyofibrillar Mitochondrial Content
2.36; 2.34; 2.1; 1.7
PRIMARY
Maximal Calcium-activated Tension Single Muscle Fiber Tension
114; 111; 112; 103; 173; 175
SECONDARY
Physical Activity Level
4167; 4767; 2088; 2500
SECONDARY
Quadriceps Muscle Cross-sectional Area
45.5; 38.8; 38.3; 33.8; 52.0; 46.0
SECONDARY
Short Physical Performance Battery
9.36; 9.80; 10.45; 10.10
SECONDARY
Knee Extensor Muscle Strength
113.0; 94.7; 65.8; 65.7; 89.9; 58.9
SECONDARY
30-second Sit-to-stand Test
10.45; 11.78; 10.55; 12.56

Summary

Total knee replacement, or arthroplasty, is the final clinical intervention available to relieve pain and functional limitations related to advanced stage knee osteoarthritis. Despite its beneficial effects, the early post-surgical period is characterized by the erosion of lower extremity muscle size and strength that cause further disability and slow functional recovery. While the detrimental effects of this period on muscle are widely recognized, the mechanisms underlying these adaptations are poorly understood and there are currently no widely-accepted clinical interventions to counter them

Eligibility Criteria

Inclusion Criteria

  • symptomatic, primary knee osteoarthritis (OA)
  • being considered for total knee arthroplasty

Exclusion Criteria

  • knee OA secondary to inflammatory/autoimmune disease
  • untreated/uncontrolled hypertension, diabetes or thyroid disease
  • chronic heart failure, actively-treated malignancy, exercise-limiting peripheral vascular disease, stroke or neuromuscular disease
  • body mass index >38 kg/m2
  • lower extremity blood clot or known coagulopathies
  • implanted pacemaker/ICD
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03051984). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search